We are live on ! Find out more
BCM

Boxer Capital Management Portfolio holdings

AUM $762M
1-Year Est. Return 1,125.36%
This Fund
S&P 500
This Quarter Est. Return
-6.27%
1 Year Est. Return
+1,125.36%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$332M
AUM Growth
-$842M
Cap. Flow
-$767M
Cap. Flow %
-230.79%
Top 10 Hldgs %
72.35%
Holding
62
New
2
Increased
2
Reduced
10
Closed
34

Top Buys

Rank Stock Value
1
SLDB icon
Solid Biosciences
SLDB
+$5.31M
2
DNLI icon
Denali Therapeutics
DNLI
+$4.79M
3
PRLD icon
Prelude Therapeutics
PRLD
+$373K
4
KOD icon
Kodiak Sciences
KOD
+$190K

Top Sells

Rank Stock Value
1
SWTX
SpringWorks Therapeutics
SWTX
+$124M
2
RVMD icon
Revolution Medicines
RVMD
+$120M
3
NUVL
Nuvalent
NUVL
+$52.4M
4
MRUS
Merus
MRUS
+$52.3M
5
AXSM icon
Axsome Therapeutics
AXSM
+$39.8M

Sector Composition

Rank Sector Weight
1 Healthcare 99.97%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SANA icon
51
Sana Biotechnology
SANA
$977M
– –
-1,545,000
Closed -$2.52M
SMMT icon
52
Summit Therapeutics
SMMT
$10.8B
– –
-250,000
Closed -$4.46M
SRRK icon
53
Scholar Rock
SRRK
$5.74B
– –
-750,000
Closed -$32.4M
SWTX
54
DELISTED
SpringWorks Therapeutics
SWTX
– –
-3,421,541
Closed -$124M
SYRE icon
55
Spyre Therapeutics
SYRE
$9.06B
– –
-466,680
Closed -$10.9M
TERN
56
DELISTED
Terns Pharmaceuticals
TERN
– –
-752,000
Closed -$4.17M
THRD
57
DELISTED
Third Harmonic Bio
THRD
– –
-2,000,000
Closed -$20.6M
TYRA icon
58
Tyra Biosciences
TYRA
$1.53B
– –
-2,027,678
Closed -$28.2M
ZNTL icon
59
Zentalis Pharmaceuticals
ZNTL
$352M
– –
-450,000
Closed -$1.36M
ZURA icon
60
Zura Bio
ZURA
$536M
– –
-300,000
Closed -$750K
BCAX
61
Bicara Therapeutics
BCAX
$1.7B
– –
-135,000
Closed -$2.35M
PSTX
62
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
– –
-2,000,000
Closed -$19.2M
1 2
3

Similar funds

GWM
Gibbs Wealth Management Alpharetta, Georgia $762M AUM 18.55% 1-Year Est. Return
TI
Think Investments San Francisco, California $762M AUM 33.1% 1-Year Est. Return
CFS
Cannon Financial Strategists Athens, Georgia $761M AUM 18.73% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return
CCIP
Camrose Capital Investment Partners London, United Kingdom $764M AUM 0.9% 1-Year Est. Return
FA
Fiducient Advisors Chicago, Illinois $765M AUM 12.73% 1-Year Est. Return
TVAMP
Tennessee Valley Asset Management Partners Knoxville, Tennessee $757M AUM 14.19% 1-Year Est. Return

Boxer Capital Management's Q1 2025 Portfolio in Review

As of Q1 2025, Boxer Capital Management held 62 positions worth $332M, down 72% from $1.17B the previous quarter. Its ten largest holdings account for 72% of the portfolio.

Boxer Capital Management withdrew a net $767M in Q1 2025, closing 34 positions and reducing 10 holdings. Its most notable exit was SpringWorks Therapeutics, an estimated $124M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier.

Against the trend, Boxer Capital Management opened a new position in Solid Biosciences worth $4.59M.

  • Boxer Capital Management's largest Q1 2025 buy was Solid Biosciences: 1,240,700 shares worth $4.59M.
  • Boxer Capital Management added most to Prelude Therapeutics in Q1 2025, an estimated $373K increase.
  • Boxer Capital Management's biggest Q1 2025 reduction was Revolution Medicines, cutting an estimated $120M.
  • Boxer Capital Management fully exited SpringWorks Therapeutics in Q1 2025, selling an estimated $124M.
  • Boxer Capital Management's ten largest holdings make up 72% of its $332M portfolio in Q1 2025.
  • Boxer Capital Management opened 2 new positions and closed 34 in Q1 2025.
  • Boxer Capital Management's portfolio value fell 72% quarter-over-quarter to $332M.

Based on Boxer Capital Management's 13F filing for Q1 2025, filed 15 May 2025.